Department of Clinical Sciences and Community Health, University of Milan, 20129 Milan, Italy.
Experimental Laboratory for Auxo-endocrinological Research, Istituto Auxologico Italiano, IRCCS, 28824 Verbania, Italy.
Nutrients. 2020 May 21;12(5):1495. doi: 10.3390/nu12051495.
In clinical practice, there is the diffuse conviction that obese subjects with metabolic syndrome may be more difficult to treat.
The aim of the present study was that to investigate the effectiveness of a 3-week in-hospital body weight reduction program (BWRP) in a large population of obese subjects with and without metabolic syndrome ( = 1922; 222 men and 1700 women, age range 18-83 yr). Outcomes such as body mass index (BMI), total (TOT) and HDL cholesterol, systolic and diastolic blood pressures (SBP and DBP, respectively), coronary heart disease (CHD) score, fatigue severity score (FSS), and stair climbing test (SCT) time were evaluated before and after the intervention (Δ). A sex-, BMI-, and age-related stratification of the obese population with or without metabolic syndrome was applied.
When compared to obese subjects without metabolic syndrome, at the basal conditions, obese subjects had a poorer cardiometabolic profile, as demonstrated by higher triglycerides, TOT-cholesterol, DBP, SBP, and CHD score, and a more compromised muscle performance (evaluated by SCT), associated with more perception of fatigue (measured by FSS). Nevertheless, obese subjects with metabolic syndrome obtained more benefits from BWRP than those without metabolic syndrome for some outcomes (i.e., ΔTOT-cholesterol, ΔSBP, and ΔCHD score). Despite these differences, the BWRP-induced weight loss was similar between the two groups (i.e., ΔBMI) as well as the gain of muscle performance (i.e., ΔSCT) and the reduction of fatigue (i.e., ΔFSS). Interestingly, the potentially deleterious fall in HDL-cholesterol levels after BWRP was less evident in obese subjects with metabolic syndrome than those without metabolic syndrome. When pooling all data, the ΔCHD score was associated with age, sex, and metabolic syndrome. The remaining outcomes, such as ΔBMI, ΔFSS, and ΔSCT time, were associated with sex and age but not with metabolic syndrome. Finally, ΔBMI was positively correlated with ΔCHD score, ΔFSS, and ΔSCT time in both obese subjects without metabolic syndrome and obese subjects with metabolic syndrome.
When comparing obese subjects undergoing a BWRP, metabolic syndrome is not a negative predictive factor affecting the effectiveness of this intervention in terms of weight loss, muscle performance, and psychological well-being.
在临床实践中,普遍认为患有代谢综合征的肥胖患者可能更难以治疗。
本研究旨在调查为期 3 周的住院体重减轻计划(BWRP)对肥胖患者(n=1922;222 名男性和 1700 名女性,年龄 18-83 岁)和代谢综合征(n=1922;222 名男性和 1700 名女性,年龄 18-83 岁)的有效性。在干预前后(Δ)评估了体重指数(BMI)、总胆固醇(TOT)和高密度脂蛋白胆固醇、收缩压和舒张压(SBP 和 DBP)、冠心病(CHD)评分、疲劳严重程度评分(FSS)和爬楼梯测试(SCT)时间等指标。对肥胖人群进行了性别、BMI 和年龄相关的分层,无论是否存在代谢综合征。
与无代谢综合征的肥胖患者相比,肥胖合并代谢综合征的患者在基础状态下存在较差的心血管代谢特征,表现为更高的甘油三酯、TOT 胆固醇、DBP、SBP 和 CHD 评分,以及更差的肌肉性能(通过 SCT 评估),同时疲劳感更强烈(通过 FSS 评估)。然而,与无代谢综合征的肥胖患者相比,肥胖合并代谢综合征的患者从 BWRP 中获益更多,表现在一些结果上(即ΔTOT 胆固醇、ΔSBP 和ΔCHD 评分)。尽管存在这些差异,但两组的 BWRP 诱导的体重减轻(即ΔBMI)、肌肉性能的提高(即ΔSCT)和疲劳的减轻(即ΔFSS)相似。有趣的是,与无代谢综合征的肥胖患者相比,BWRP 后高密度脂蛋白胆固醇水平的潜在下降在肥胖合并代谢综合征的患者中不那么明显。当汇总所有数据时,ΔCHD 评分与年龄、性别和代谢综合征相关。其余结果,如ΔBMI、ΔFSS 和ΔSCT 时间,与性别和年龄相关,但与代谢综合征无关。最后,在无代谢综合征和合并代谢综合征的肥胖患者中,ΔBMI 与ΔCHD 评分、ΔFSS 和ΔSCT 时间呈正相关。
在比较接受 BWRP 的肥胖患者时,代谢综合征并不是影响该干预措施在体重减轻、肌肉性能和心理健康方面有效性的负面预测因素。